Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05409183 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of CRD-740 in Heart Failure
A Phase 2 study, sponsored by Cardurion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT05409183 is a Phase 2 study that was terminated before completion, run by Cardurion Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT05409183, a Phase 2 study, was terminated before completion, sponsored by Cardurion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment. The primary objective in Part A is to assess the effect of CRD-740 compared to placebo in plasma cGMP at Week 4 in HFrEF. Part B of the study was not conducted in favor of redesigned new studies.
Interventions
- DRUG Placebo
- DRUG CRD-740
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-05-26 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05409183
The ClinicalTrials.gov registry entry for NCT05409183 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardurion Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05409183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05409183 about?
NCT05409183 is a clinical study titled "Effectiveness of CRD-740 in Heart Failure". This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment. The primary objective in Part A is to assess the effect of CRD-740 compared to p...
What is the current status of trial NCT05409183?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-05-26. Estimated completion is 2023-07-25.
What interventions are being tested in trial NCT05409183?
The interventions under investigation include: Placebo (DRUG), CRD-740 (DRUG).
Who is sponsoring clinical trial NCT05409183?
This trial is sponsored by Cardurion Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.